GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to test whether mild (Child-Pugh A, score 5-6) and
moderate (Child-Pugh B, score 7-9) hepatic impairment affects pharmacokinetics, safety and
tolerability of GP681, compared with a control group with normal hepatic function following
oral administration of GP681 as single dose.